Global Prefilled Syringes Market was valued at US$ 1,432.2 million in 2020 and is anticipated to reach US$ 3,301.1 million by 2027 displaying an elevated CAGR of 10% over the forecast period ...

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a ...

Fourteen products delivered at least double-digit sales growth in the quarter, including Repatha, BLINCYTO, and TEZSPIRE. The company’s newly launched IMDELLTRA generated $81 million in sales. For the ...

THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis and Blincyto among others. However, prices of most products are expected to ...

The upcoming report from Amgen (AMGN) is expected to reveal quarterly ... According to the collective judgment of analysts, 'Product Sales- Repatha- Total' should come in at $616.47 million.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

The Fund aims to provide a higher total return (the combination of capital growth and income), net of the Ongoing Charge Figure, than that of the MSCI ACWI Index over any five-year period. The Fund ...

the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges – including isolator technology for these formats – as well as high ...